Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis PatientsBusiness Wire • 06/28/21
Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic FibrosisBusiness Wire • 06/25/21
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del MutationBusiness Wire • 06/18/21
Nasdaq, Smartsheet, Twilio, Vaxart, Zoom Video and More Friday Afternoon Analyst Calls24/7 Wall Street • 06/11/21
Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy TrialsBenzinga • 06/11/21
Vertex Pharmaceuticals stock tumbles to pace S&P 500 losers after disappointing drug trial dataMarket Watch • 06/11/21